Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy - 30/03/13
![](/templates/common/images/mail.png)
Disclosure of potential conflict of interest: P. M. Villiger has board memberships with Roche, Novartis, Pfizer, Merck Sharp & Dohme, Abbott, Bristol-Myers Squibb, UCB, and Grünenthal; is employed by the University of Bern; and has received grants from the Swiss National Science Foundation and Lichtensteinstiftung. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 4
P. 1235 - avril 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?